Sobi的收入在2025年的Q3增加了21%, Sobi's revenue rose 21% in Q3 2025, driven by key drugs, despite a charge on Vonjo; full-year outlook raised.

瑞典孤儿Biovitrum(Sobi)报告2025年第三季度收效强劲,按不变汇率计算,收入增长21%,其驱动因素是Altuvoct、Doptelet、Gamivant和Kineret的强劲销售。 Swedish Orphan Biovitrum (Sobi) reported strong third-quarter 2025 results, with revenue up 21% at constant exchange rates, driven by robust sales of Altuvoct, Doptelet, Gamifant, and Kineret. 血液学和免疫学部门的业务增长显著,而Vonjo的大量非现金减值费影响了净利. Hematology and immunology divisions saw significant growth, while a large non-cash impairment charge for Vonjo impacted net earnings. 经调整的EBITA差值达到47%,公司提高了全年前景展望,现在预测收入增长率为低两位数,经调整的EBITA差值在中到高30年代幅度内为低位数。 Adjusted EBITA margin reached 47%, and the company raised its full-year outlook, now projecting low double-digit revenue growth and an adjusted EBITA margin in the mid-to-high 30s range.